The efficacy of 40 mg versus dose de-escalation to less than 40 mg of afatinib (Giotrif) as the first-line therapy for patients with primary lung adenocarcinoma harboring favorable epidermal growth factor mutations.
| Image |  |
|---|---|
| Description | scientific article published on 27 June 2017 |
| Author/s |
author: Chih-Hung Chen |
| Publication date | June 27, 2017 |
| Language | English |
| Country of origin | |
| Wikipedia link | |
| Copyright status | |
| Missing/wrong data? | Edit Wikidata item |